Impact of Estradiol on Endothelial Function in Peri-Menopausal Women

University of Delaware

Status and phase: Active, not recruiting; Phase 4

Conditions: Estrogen; Vasodilation; Perimenopause

Treatments: Drug: Estradiol (mylan or vivelle dot patch); Other: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT04255160

R01HL146558 (U.S. NIH Grant/Contract)

1508142

Details and patient eligibility

About

The purpose of this study is to identify the impact of estradiol (E2) on the mechanisms that regulate vascular endothelial function in peri-menopausal (PERI) women. This study is the first step in understanding factors contributing to endothelial dysfunction in women with advancing reproductive age and in response to E2 administration.

Full description

Cardiovascular disease (CVD) is the leading cause of death in women. Although overall CVD-related mortality has declined, there has been an increase in CVD mortality in women aged 35-54 years, prior to menopause. It is unclear what contributes to this increased mortality rate, and is a significant problem for women's health. Endothelial function is considered a biomarker of cardiovascular health; declines in endothelial function are considered a precursor to the development of atherosclerosis and CVD. Thus, changes in endothelial function in women as they advance through reproductive stages towards menopause may play a role in the greater prevalence of CVD mortality. However, very few studies have focused on cardiovascular health in women leading up to menopause, during the PERI transition. The PERI period is a critical time point where reproductive hormones and ovarian function change rapidly. Recent data demonstrate that endothelial function begins to decline during PERI. Furthermore, despite women being of similar biological age, significant differences in endothelial function were noted when classified based on reproductive age - specifically between early PERI and late PERI. These data show that the decline initially occurs in the early PERI phase, making this a key time point for intervention to offset the future development of CVD. Our central hypothesis is that increased Endothelin-1 (ET-1) and a loss of Endothelin-1 B (ETB) mediated vasodilation play a primary role in contributing to impaired endothelial function with advancing reproductive age. We will assess macro- and micro- vascular endothelial function, assess intracellular ET-1 protein and ETB receptor expression in harvested endothelial cells from peripheral veins, and use the cutaneous circulation as an in vivo model to explore the receptor mechanisms (ETBR and ETAR) in early and late PERI in response to E2 or placebo.

Enrollment: 80 estimated patients

Sex: Female

Ages: 40 to 58 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Peri-menopausal women between 40-58 years of age with variable cycles as defined by increase in cycle length of greater than 7 days within ten consecutive cycles, or amenorrhea for more than 2 months, but less than 12 months.

Exclusion criteria

• Women who are pregnant, planning on becoming pregnant, or are breast feeding;
• Women who have a history of cardiovascular disease, blood clots (e.g, pulmonary embolism or deep vein thrombosis), stroke, cancer, or liver disease;
• Women who have a body mass index less than 18 or greater than 35kg/m2;
• Women who use tobacco products;
• Women who's blood pressure is greater than 140/90 mmHg, have been diagnosed by a physician with hypertension or are taking medication for high blood pressure;
• Women who have a neurological disease, or diabetes;
• Women who have had a hysterectomy or have used hormones (birth control or hormone replacement) within the past 3 months;
• Women who have a latex allergy.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

80 participants in 2 patient groups, including a placebo group

Estradiol

Experimental group

Description:

Transdermal estradiol (0.1mg/day patch)

Treatment:

Drug: Estradiol (mylan or vivelle dot patch)

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Other: Placebo